Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

13. Juni 2019 07:00 ET | Quelle: Orchestra BioMed

Orchestra BioMed™ Announces Global Strategic Partnership with Terumo Corporation for Development and Commercialization of Virtue® Sirolimus-Eluting Balloon

Virtue® SEB is expected to become a flagship therapeutic product for Terumo and will strengthen its broad US and global portfolio of interventional solutionsTerms of the partnership include...
23. Mai 2019 07:30 ET | Quelle: Orchestra BioMed

Orchestra BioMed™ Presents Clinical Data at EuroPCR 2019 Demonstrating Safety and Efficacy of BackBeat Cardiac Neuromodulation Therapy (CNT)

Novel implantable bioelectronic treatment delivers immediate, substantial, and sustained reduction in blood pressureData showed 14.2 mmHg reduction in 24-hour ambulatory systolic blood pressure at...
24. April 2019 09:00 ET | Quelle: Orchestra BioMed

Orchestra BioMed™ Receives FDA Breakthrough Device Designation for Virtue® Sirolimus-Eluting Balloon (SEB)

First and only non-coated sirolimus-eluting angioplasty balloon system to show promising clinical resultsPotential to offer significant advantages for treatment of coronary in-stent restenosis (ISR),...

Vorherige Seite